These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30713795)

  • 1. Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile.
    Strasser K; Birnleitner H; Beer A; Pils D; Gerner MC; Schmetterer KG; Bachleitner-Hofmann T; Stift A; Bergmann M; Oehler R
    Oncoimmunology; 2019; 8(2):e1537693. PubMed ID: 30713795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral FoxP3
    Syed Khaja AS; Toor SM; El Salhat H; Ali BR; Elkord E
    Front Immunol; 2017; 8():619. PubMed ID: 28603527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal cancer-infiltrating T lymphocytes display a distinct chemokine receptor expression profile.
    Löfroos AB; Kadivar M; Resic Lindehammer S; Marsal J
    Eur J Med Res; 2017 Oct; 22(1):40. PubMed ID: 29020986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
    Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
    Front Immunol; 2019; 10():2936. PubMed ID: 31921188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer.
    Ugai T; Väyrynen JP; Lau MC; Borowsky J; Akimoto N; Väyrynen SA; Zhao M; Zhong R; Haruki K; Dias Costa A; Fujiyoshi K; Arima K; Wu K; Chan AT; Cao Y; Song M; Fuchs CS; Wang M; Lennerz JK; Ng K; Meyerhardt JA; Giannakis M; Nowak JA; Ogino S
    Cancer Immunol Immunother; 2022 Apr; 71(4):933-942. PubMed ID: 34529108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Higher Frequency of CD14+ CD169+ Monocytes/Macrophages in Patients with Colorectal Cancer.
    Li C; Luo X; Lin Y; Tang X; Ling L; Wang L; Jiang Y
    PLoS One; 2015; 10(10):e0141817. PubMed ID: 26509874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of Regulatory T-Cells and Other Phenotypes of T-Cells in Tumors and Regional Lymph Nodes of Colorectal Cancer Patients.
    Kazama K; Otake J; Satoyoshi T; Shiozawa M; Sugano N; Sato S; Atsumi Y; Kano K; Murakawa M; Maezawa Y; Hashimoto I; Numata M; Oshima T; Yukawa N; Rino Y; Sasada T; Masuda M
    In Vivo; 2020; 34(2):849-856. PubMed ID: 32111794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
    Cantero-Cid R; Casas-Martin J; Hernández-Jiménez E; Cubillos-Zapata C; Varela-Serrano A; Avendaño-Ortiz J; Casarrubios M; Montalbán-Hernández K; Villacañas-Gil I; Guerra-Pastrián L; Peinado B; Marcano C; Aguirre LA; López-Collazo E
    BMC Cancer; 2018 Oct; 18(1):945. PubMed ID: 30285662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
    Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
    Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer.
    Timperi E; Pacella I; Schinzari V; Focaccetti C; Sacco L; Farelli F; Caronna R; Del Bene G; Longo F; Ciardi A; Morelli S; Vestri AR; Chirletti P; Barnaba V; Piconese S
    Oncoimmunology; 2016 Jul; 5(7):e1175800. PubMed ID: 27622025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
    Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.
    Zhou G; Noordam L; Sprengers D; Doukas M; Boor PPC; van Beek AA; Erkens R; Mancham S; Grünhagen D; Menon AG; Lange JF; Burger PJWA; Brandt A; Galjart B; Verhoef C; Kwekkeboom J; Bruno MJ
    Oncoimmunology; 2018; 7(7):e1448332. PubMed ID: 29900067
    [No Abstract]   [Full Text] [Related]  

  • 20. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
    Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B
    Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.